College of Traditional Chinese medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Research Center for Infectious Diseases, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Front Immunol. 2022 Jul 15;13:961796. doi: 10.3389/fimmu.2022.961796. eCollection 2022.
Immunotherapy is one of the promising strategies in the treatment of oncology. Immune checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical treatment of patients with pMMR/MSS/MSI-L mCRC alone. Therefore, there is an urgent need to find combination therapies that can improve the response rate of immune checkpoint inhibitors. Oncolytic viruses are a new class of cancer drugs that, in addition to directly lysing tumor cells, can facilitate the action of immune checkpoint inhibitors by modulating the tumor microenvironment and transforming "cold" tumors into "hot" ones. The combination of oncolytic viruses and immune checkpoint inhibitors is currently being used in several primary and clinical studies to treat tumors with exciting results. The combination of genetically modified "armed" OV with ICIs is expected to be one of the treatment options for pMMR/MSS/MSI-L mCRC. In this paper, we will analyze the current status of oncolytic viruses and ICIs available for the treatment of CRC. The feasibility of OV in combination with ICI for CRC will be discussed in terms of the mechanism of action of OV in treating tumors.
免疫疗法是肿瘤治疗中很有前途的策略之一。免疫检查点抑制剂作为一种免疫疗法，单独用于错配修复蛋白（pMMR）/微卫星稳定（MSS）/微卫星高度不稳定（MSI-H）结直肠癌患者的临床治疗中疗效并不显著。因此，迫切需要寻找能够提高免疫检查点抑制剂反应率的联合治疗方法。溶瘤病毒是一类新型的癌症药物，除了直接裂解肿瘤细胞外，还可以通过调节肿瘤微环境将“冷”肿瘤转化为“热”肿瘤，从而促进免疫检查点抑制剂的作用。溶瘤病毒与免疫检查点抑制剂的联合应用目前正在进行一些基础和临床研究，以治疗肿瘤，取得了令人兴奋的结果。与 ICI 联合使用基因修饰的“武装”OV 有望成为 pMMR/MSS/MSI-L mCRC 的治疗选择之一。本文将分析目前可用于 CRC 治疗的溶瘤病毒和 ICI 的现状。将从 OV 治疗肿瘤的作用机制方面，讨论 OV 与 ICI 联合用于 CRC 的可行性。
